Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

NCT00105092 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: Enzastaurin HCL

Sponsor

Eli Lilly and Company